Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Stomach Neoplasms 2Pancreatic Neoplasms 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Sarcoma, Synovial 1Prostatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid 1Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Burkitt Lymphoma 1

Interventions

pembrolizumab 9Nivolumab 5tislelizumab 2spartalizumab 2belinostat 2atezolizumab 2Pemetrexed 2Paclitaxel 2Ipilimumab 2Fluorodeoxyglucose F18 2Docetaxel 2Cisplatin 2tocilizumab 1sargramostim 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1epacadostat 1enzalutamide 1durvalumab 1cabozantinib 1bosutinib 1Sorafenib 1Sirolimus 1Quality of Life 1Plicamycin 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Immunotherapy, Adoptive × Genitourinary × Clear all
NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡